Sultan of Johor Invests in Pharmaceutical Manufacturing Zone in Sri Lanka

IMG_0254

On 8th January 2018, the State Pharmaceuticals Manufacturing Corporation of Sri Lanka (SPMC) and Pharma Zone (Pvt) Ltd entered into an agreement to build the first ever exclusive pharmaceutical manufacturing zone of Sri Lanka in the Welipenna area of the Kalutara district at an investment in excess of US $ 10 million.

Pharma Zone (Pvt) Ltd , located on 50 acres is a BOI approved company whose principals are His Majesty the Sultan of Johor, Sultan Ibrahim Ismail Ibni Sultan Iskandar and Mr. Patrick Lim Soo Kit, a leading Malaysian entrepreneur. It is His Majesty’s desire that this investment results not only in commercial success but also that it will benefit as many Sri Lankan citizens and promote closer commercial and diplomatic relations between the people of Sri Lanka and Johor.

The Sultan’s investment vehicle, Inti Kemuncak Sdn Bhd is a well-established property development company based in Malaysia focusing on large scale property development in the Asian region. Inti Kemuncak is the innovative developer of major townships and urban regeneration projects including Coronation Square, a US $ 1.2 billion international class urban mixed development located within the prestigious Ibrahim International Business District (IIBD) in Johor Bahru

The Hon Minister of Health, Dr. Rajitha Senaratne along with other representatives of the SPMC and Pharma Zone (Pvt) Ltd participated in the event which was held at Waters Edge. The Pharma Zone will facilitate the local pharmaceutical manufacturers with sufficient land for manufacturing plants and basic infrastructure facilities for the manufacture of pharmaceutical products with a view to achieving the Government’s target of localising production of essential pharmaceutical items to a value of US$100 million, thus saving valuable foreign exchange.

The Hon Minister of Health, Dr. Rajitha Senaratne expressed his gratitude to the Sultan and the people of Johor Malaysia for making the Pharma Zone a reality. He said that the establishment of the Pharma Zone by His Majesty the Sultan of Johor would hopefully give confidence and encourage other overseas investors to follow suit.

“We are delighted to enter into this agreement with the government of Sri Lanka which has always enjoyed warm relations with Malaysia. It is the fervent wish of His Majesty Sultan Ibrahim, that this venture not only brings commercial prosperity to Sri Lanka but benefits the people by way of reduced pricing as well as the ready availability of drugs”, said Mr Lim speaking on the occasion. “This is a 100 % Malaysian investment and it underlines the high regard that the Sultan and the people of Johor for Sri Lanka”.

Chairman  SPMC, Dr. Sayura Samarasundara said that with the completion of the Pharma  Zone, envisaged to be in operation within one year, the Country’s dependency on imported drugs will soon become a thing of the past.

The Zone will be run and administered by Pharma Zone, headed by Mr Patrick Lim Soo Kit, while the SPMC along with the Ministry of Health will set the standards and monitor quality.

Electricity, water, road infrastructure, security, waste water management, etc will all be provided to the companies operating within the Zone, and it is the intention of Pharma Zone to attract overseas investors to set up operations within the Zone as well. “We will be marketing Pharma Zone regionally,” said Mr Lim.

With the establishment of Pharma Zone it is hoped that most of Sri Lanka’s drug availability and cost issues will soon come to an end.




About us

Lanka Business News is amongst the leading online Business News portals in Sri Lanka, unique for its focus on contemporary business news relevant across multiple industries operating in the country. We present not only the news, but a perspective based on observations and possible implications of a prevailing news item. LBN also provides an insight to the impact of a global economic or industrial development, thus helping stakeholders make informed and calculated decisions.




Follow Us


Newsletter